BRCA1 and ovarian carcinoma: The orally active PARP-1 inhibitor Fluzoparib (SHR3162) exhibits an IC50 of 1.46 ± 0.72 nM in cell-free assays, and exhibits promising antitumor activity due to its ability to selectively impair the proliferation of cells exhibiting HR deficiencies, sensitizing HR-deficient and HR-proficient cells to exposure to other cytotoxic compounds or treatments. In vivo work suggests that Fluzoparib exhibits promising pharmacokinetic characteristics and that it is applicable for use in research focused on BRCA1/2-mutant relapsed ovarian cancer